Vinorelbine tartrate is under clinical development by Laboratoires Pierre Fabre and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Vinorelbine tartrate’s likelihood of approval (LoA) and phase transition for Malignant Pleural Mesothelioma took place on 25 Jun 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vinorelbine tartrate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Vinorelbine tartrate overview

Vinorelbine tartrate (Navelbine, Vinorelbine, Carcyt) is a semi-synthetic derivative of a vinca alkaloid acts as anti-mitotic agent. It is formulated as soft gelatin capsules for oral route of administration and solution, concentrate solution for intravenous route of administration. It is indicated as a single agent or in combination with cisplatin for first-line treatment of stage 3 or 4 non-small cell lung cancer. It is also indicated for the treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen. It is also indicated as a single agent or in combination for the first line treatment of stage 3 or 4 non-small cell lung cancer, treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline-containing regimen. Vinorelbine tartrate is also under development for the treatment of metastatic hormone receptor positive (HR+), human epidermal growth factor receptor2 negative (HER2-) breast cancer and triple negative breast cancer and malignant pleural mesothelioma. It is also indicated in metastatic prostate cancer.

Laboratoires Pierre Fabre overview

Laboratoires Pierre Fabre (Pierre Fabre), a subsidiary of Pierre Fabre Foundation that develops products and solutions including health and beauty. Its comprehensive product portfolio comprises of a range of complementary products, from prescribed drugs to dermo-cosmetics, including over-the-counter drugs and natural health products. The company’s products address the full spectrum of health care needs from pathologies such as cancer or topical dermatitis to rare diseases including pediatric hemangioma, family hygiene to skin, hair and scalp care; and from day-to-day illnesses. Pierre Fabre sells and markets its products under various brands, including Derma, Galenic Klorane, Avene, Ducray and Rene Furterer, among others. Pierre Fabre is headquartered in Paris, Ile-de-France, France.

Quick View Vinorelbine tartrate LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Vinorelbine tartrate
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Marketed

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.